Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ACD’s RNAscope® In Situ Hybridization Technology Gains Significant Traction

Published: Wednesday, July 16, 2014
Last Updated: Tuesday, July 15, 2014
Bookmark and Share
Highly sensitive and easy-to-use technology validated in over 100 papers in three years.

Advanced Cell Diagnostics Inc. (ACD) has announced that its RNAscope® RNA in situ hybridization technology has reached two major milestones.

In just three years, over 100 peer-reviewed papers featuring the technology have been published, and with the significant increase in use of RNAscope, ACD has now built a library of over 4000 target probes for numerous species.

Probes are designed to order in under two weeks, and in just six months the library has grown by over 1500, reflecting the wide interest in ACD’s breakthrough technology.

RNAscope uniquely has the sensitivity to enable researchers to detect in situ single RNA molecules and provide quantitative analysis of gene expression at a single cell level. In addition, the technology provides morphological context by showing spatial and cell-specific expression while preserving tissue architecture.

RNAscope’s ability to unlock the full potential of RNA biomarkers, together with its highly reproducible and easy-to-use technology, has resulted in an average of over 6 papers a month published so far in 2014 - a rate that is doubling every year.

Now in wide use throughout academia and industry, the papers range from basic research in developmental biology, neuroscience and stem cells to clinical research such as cancer biomarkers, infectious diseases and ophthalmology, in respected journals such as Nature, Science, Cell, PLoS One, PNAS and Clinical Cancer Research.

Localizing and quantifying RNA sequences in the context of cells and tissues is a fundamental approach in molecular biology. RNAscope makes it accessible to researchers of any level of experience, as Alexey Pronin, PhD of the University of Miami School of Medicine, who recently published in PLoS One, explained. “Even though I had no previous experience of in situ hybridization, the RNAscope assay was easy to perform and worked first time, allowing us to confirm the expression of three different genes in the mouse eye that we had previously identified via transcriptomics. Importantly, the multiplex assay showed that two of the genes are expressed in two separate cell layers of the eye blood vessels – information that would be hard to get using other technologies.”

“Publications from our customers are particularly exciting, as it shows the growing validation and adoption of our technologies at the forefront of scientific research”, said Xiao-Jun Ma, ACD’s CSO. “And with our probe catalog growing by 240% in the last year, targeting more than 4,000 genes in many species, it’s a real testament to the demand for our technology, our fast probe development times and the scalability of our platform. Together, these two milestones are a comprehensive validation of the effectiveness of RNAscope technology. In this age of single-cell transcriptomics, RNA in situ hybridization will prove to be indispensable in the effort to characterize the many newly discovered genes, especially the vast repertoire of noncoding RNA genes. We believe that the specific benefits of RNAscope technology will undoubtedly accelerate the translation of genomic discoveries to clinical medicine including new therapeutics and diagnostics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Advanced Cell Diagnostics Launches New Website and Online Store
Better serving the scientific community, the new site is equipped with a fresh design and interactivity, and features e-commerce capabilities.
Tuesday, October 13, 2015
ACD Completes $22 Million Series C Equity Financing
Proceeds will accelerate commercialization and launch of new technology platforms.
Friday, June 19, 2015
Advanced Cell Diagnostics Appoints Tom Olenic as Chief Commercial Officer
Advanced Cell Diagnostics, Inc. (ACD) has announced the appointment of Tom Olenic to its executive leadership team as Chief Commercial Officer.
Tuesday, December 02, 2014
MicroMatrices, Advanced Cell Diagnostics Partnership
MicroMatrices becomes preferred partner for preclinical use of ACD’s RNA ISH.
Monday, November 10, 2014
ACD Awarded $1.4 Million NCI Grant
Two-year grant to develop ultrasensitive diagnostic test for B-Cell lymphoma.
Wednesday, October 08, 2014
ACD Establishes Subsidiary to Serve the European Market
Subsidiary will enable easy ordering, fast delivery and enhanced support for EU customers
Monday, September 15, 2014
ACD Receives ISO Certification
ACD’s ISO 13485:2003 certification covers the design, development, production, and commercialization of ACD’s proprietary RNAscope® product lines.
Tuesday, August 12, 2014
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!